1. $AbbVie(ABBV)$
ABBV 1Q returns to top line growth
1Q YoY
Revenue +0.7% ($12.3 B, above guidance)
Humira -36%
Skyrizi +48%
Rinvoq +59%
Net income +473%
Dil. EPS +492% (adj -6%)
Raises Adj. dil. EPS guidance for FY24 from $10.97 - $11.17 to $11.13 - $11.33
ABBV 1Q highlight
Returning to revenue growth a year after Humira lost exclusivity in the US
Humira in FY22 was the highest selling drug in the world
Image
2. $Intel(INTC)$
INTC 1Q Data center
-10% (DCAI+Altera combined) YoY
Image
INTC modified the segment reporting line
DCAI 2023 = in 2024 to (DCAI+Altera)
Image
https://twitter.com/DividendWave/status/1783825440299204782
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments